Navigation Links
Anthera Announces First Quarter 2013 Financial Report and Conference Call
Date:5/3/2013

HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13th. Anthera will host a Corporate Update conference call on May 20th, 2013.

Conference Call Access:
Date:   Monday, May 20th, 2013
Time:   5:00 pm Eastern Time

Domestic Dial-in:        (877)312-8807
International Dial-in:   (253)237-1190
Conference ID:           64577060

To access the 24-hour audio replay, U.S. and Canadian participants may dial (855)859-2056; international participants may dial (404)537-3406.  The conference ID for the replay is 64577060. The audio replay will be available until May 27th, 2013. 

About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510-856-5598.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCalls Microscope
2. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
3. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
4. Anthera to Report Second Quarter 2012 Financial Results
5. Life Technologies Announces First Quarter 2013 Results
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. BioLife Solutions Announces License Agreement
9. PRIM&R Announces Longtime Leader to Step Down
10. MiMedx Announces Record First Quarter 2013 Results
11. ViroPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Md. , and INDIANAPOLIS , Feb. 10 ... Corporation (Nasdaq: UTHR ), announced today that it has ... development of ImmuneWorks, lead compound, IW001, a purified bovine Type ... Fibrosis (IPF) and Primary Graft Dysfunction (PGD) in patients receiving ...
... Early ... ... 10, 2010 -- Companies in the Life Sciences sector, which includes the biotechnology and ... the relative strength of the sector during the economic downturn, according to PricewaterhouseCoopers LLP ...
... , , - Additional AeroLEF patents granted in ... , MISSISSAUGA, ON , Feb. 10 /PRNewswire-FirstCall/ ... it has been granted two additional patents in the US ... liposome-encapsulated fentanyl in development for the treatment of moderate to ...
Cached Biology Technology:Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 3Life Sciences Venture Capital Funding Overcomes Record Lows, Outpaces Other Sectors, According to PricewaterhouseCoopers 2Life Sciences Venture Capital Funding Overcomes Record Lows, Outpaces Other Sectors, According to PricewaterhouseCoopers 3Life Sciences Venture Capital Funding Overcomes Record Lows, Outpaces Other Sectors, According to PricewaterhouseCoopers 4YM BioSciences granted two US patents for AeroLEF(R) 2YM BioSciences granted two US patents for AeroLEF(R) 3YM BioSciences granted two US patents for AeroLEF(R) 4
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Monitor: North America Perimeter Security Systems Market" report to ... The North American perimeter security market is estimated to ... Although the U.S. market holds a larger share in this ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Scientists have shown for the first time that carbon nanotubes ... The new technique could change the way doctors treat broken ... into a fracture to promote healing. , The report appears ... journal Chemistry of Materials. ACS is the world's largest scientific ...
... you burned your finger on a hot stove? Imagine what ... or feet all the time and know there's virtually nothing ... neuropathic pain, and it's a common complication of many diseases ... this type of pain, which is caused by damage to ...
... Diego biochemists have developed a computer program that helps ... play different roles in a wide range of cellular ... , Prior to the UCSD team's findings, which ... journal Science, many scientists expressed doubts that a computational ...
Cached Biology News:Nanotubes inspire new technique for healing broken bones 2Nanotubes inspire new technique for healing broken bones 3Scientists use gene transfer technology and common virus to block neuropathic pain in animals 2Scientists use gene transfer technology and common virus to block neuropathic pain in animals 3Scientists use gene transfer technology and common virus to block neuropathic pain in animals 4Scientists use gene transfer technology and common virus to block neuropathic pain in animals 5Computer modeling reveals hidden conversations within cells 2Computer modeling reveals hidden conversations within cells 3
... The OneSTrEP Protein Interaction Kit provides ... step method to isolate intact protein ... tedious optimization or multiple purification steps, ... highly selective StrepTactin Superflow Column for ...
Liquid. Phycoerythrin conjugate is in PBS, pH 7.4 containing 1% BSA and 0.1% sodium azide....
Request Info...
... DNA Ladder is suitable for ... to 16 kb by agarose ... can be visualized by ethidium ... be detected on Southern blots ...
Biology Products: